Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.

Leukemia research - 1 Nov 2023

Zhao Davidson, Zhou Qianghua, Zarif Mojgan, Eladl Entsar, Wei Cuihong, Atenafu Eshetu G, Schuh Andre, Tierens Anne, Yeung Yu Wing Tony, Minden Mark D, Chang Hong

Abstract excerpt

AML with CEBPA mutation and AML with in-frame bZIP CEBPA mutations define favorable-risk disease entities in the proposed 5th edition of the World Health Organization Classification (WHO-HAEM5) and the International Consensus Classification (ICC), respectively. However, the impact of these new classifications on clinical practice remains unclear. We sought to assess the differences between the ICC and WHO-HAEM5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CCAAT-Enhancer-Binding Proteins
Share to Consensus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Prognosis

Share to World Health Organization

Source

Identifiers

PMID: 37690321
DOI: 10.1016/j.leukres.2023.107376

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AML with CEBPA mutations: A comparison of ICC and WHO-HAEM5 criteria in patients with 20% or more blasts.PMID 37690321Read ↗

CEBPA bZIP in-frame mutations in acute myeloid leukemia: prognostic and therapeutic implicationsSemantic proximity Read ↗

[Type of CEBPA mutations in acute myeloid leukemia and their effect on prognosis].Semantic proximity Read ↗

CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment.Semantic proximity Read ↗

CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.Semantic proximity Read ↗

[Prognostic significance of CEBPA gene mutations in acute myeloid leukemia].Semantic proximity Read ↗

How I treat AML incorporating the updated classifications and guidelines.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.Semantic proximity Read ↗

Practical considerations in clinical application of WHO 5th and ICC classification schemes for acute myeloid leukemia.Semantic proximity Read ↗

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.Semantic proximity Read ↗

Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged <60 years.Semantic proximity Read ↗

Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.